Not a good buy right now for an impatient entry: the trend is bullish, but momentum is stretched (RSI ~73) and near-term pattern stats skew slightly negative over the next week/month.
Upside is capped near resistance (R1 164.92, R2 ~168.36) while the better risk/reward entry is closer to the pivot (159.35) or S1 (~153.79).
Options positioning is mixed (bullish open-interest skew but bearish volume skew) with very elevated IV, suggesting traders are paying up for hedges/speculation into the next catalyst (earnings).
Technical Analysis
Trend: Bullish structure with SMA_5 > SMA_20 > SMA_200, indicating a sustained uptrend.
Momentum: MACD histogram +0.482 and expanding (bullish continuation), but RSI_6 at 73.0 signals the stock is short-term overextended.
Levels: Pivot 159.35 (key line in the sand); resistance at 164.92 then 168.36; supports at 153.79 then 150.35.
Price context: Pre-market 162.25 sits below the first resistance (164.92), implying less immediate upside before hitting supply.
Pattern-based forward look: Similar-pattern stats imply ~60% chance of mild drift lower (next day -0.24%, next week -0.75%, next month -2.17%).
Sentiment snapshot: Open-interest put/call ratio 0.4 is bullish (more call positioning outstanding), but the put/call volume ratio 1.63 is bearish for today’s flow (puts dominating today’s trading).
Volatility: IV30 ~51.7 vs historical vol ~25.6 (options priced rich); IV percentile ~87.7 indicates volatility is elevated versus its own history.
Activity: Today’s volume is modest (21 contracts), but open interest is elevated (7,629) with an unusually high “today vs OI avg 30D” reading, consistent with positioning/rolls ahead of a catalyst.
Technical Summary
Sell
4
Buy
10
Positive Catalysts
on 2026-02-25 after hours could serve as a catalyst if results/guide beat expectations.
Neutral/Negative Catalysts
increase pullback risk near resistance.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: $1.001B, up +120.65% YoY (very strong top-line growth).
Net income: $66M, up +69.67% YoY (profit growth strong, but slower than revenue).
EPS: $1.26, up +4.13% YoY (EPS lagging revenue/net income growth).
Gross margin: 35.93%, down -0.33% YoY (mild compression).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so a verified trend in Wall Street upgrades/downgrades cannot be assessed here.
Wall Street-style balanced view from the available data:
Pros: strong YoY revenue and net income growth; bullish technical trend.
Cons: short-term overbought setup; margin slightly down; options market pricing elevated risk into earnings; no recent institutional/insider/congress buying signals provided.
Wall Street analysts forecast JBTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JBTM is 180 USD with a low forecast of 180 USD and a high forecast of 180 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast JBTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JBTM is 180 USD with a low forecast of 180 USD and a high forecast of 180 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 162.920
Low
180
Averages
180
High
180
Current: 162.920
Low
180
Averages
180
High
180
William Blair
Ross Sparenblek
Market Perform -> Outperform
upgrade
AI Analysis
2025-08-06
Reason
William Blair
Ross Sparenblek
Price Target
AI Analysis
2025-08-06
upgrade
Market Perform -> Outperform
Reason
William Blair analyst Ross Sparenblek upgraded JBT Marel to Outperform from Market Perform. The firm sees a "compelling setup" post the company's Q2 report. The analyst believes JBT's setup is de-risked with its first two quarters progressing "better than feared."